Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 5

Aripiprazole in the treatment of Huntington’s disease: a case series

Authors Andrea Ciammola, Jenny Sassone, Clarissa Colciago, Niccolò E Mencacci, Barbara Poletti, et al

Published 25 November 2008 Volume 2009:5 Pages 1—4


Review by Single-blind

Peer reviewer comments 4

Andrea Ciammola1, Jenny Sassone1, Clarissa Colciago1, Niccolò E Mencacci1, Barbara Poletti1, Andrea Ciarmiello2, Ferdinando Squitieri3, Vincenzo Silani1

1Department of Neurology and Laboratory of Neuroscience, “Dino Ferrari” Centre, University of Milan Medical School – IRCCS Istituto Auxologico Italiano, Milano, Italy; 2Unit of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italy; 3Neurogenetics Unit, IRCCS Neuromed, Pozzilli (IS), Italy

Objectives: The aim of the study was to describe the effects of aripiprazole, a new atypical antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive functions in patients with genetically confirmed Huntington’s disease (HD).

Methods and results: Three HD patients were evaluated for Unified Huntington Disease Rating Scale part I and II and Beck Depression Inventory at baseline, after two months and one-year treatment. Aripiprazole effectively controlled involuntary movements and psychiatric symptoms, with effects on cognitive functions.

Conclusions: Our case reports suggest that aripiprazole is well tolerated, remarkably improving some of the motor and behavioral symptoms in patients affected by HD. Randomized, controlled, long-term studies are warranted.

Keywords: Huntington’s disease, aripiprazole, treatment, chorea

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

The clinical psychologist and the management of inpatient pain: a small case series

Childs SR, Casely EM, Kuehler BM, Ward S, Halmshaw CL, Thomas SE, Goodall ID, Bantel C

Neuropsychiatric Disease and Treatment 2014, 10:2291-2297

Published Date: 2 December 2014

Elongation of pulse width as an augmentation strategy in electroconvulsive therapy

Kawashima H, Suwa T, Murai T, Yoshioka R

Neuropsychiatric Disease and Treatment 2014, 10:2009-2014

Published Date: 23 October 2014

Parental bonding and attitudes toward suicide among medical college students in Japan

Hashimoto K, Sugawara N, Tanaka O, Nakamura K, Yasui-Furukori N

Neuropsychiatric Disease and Treatment 2014, 10:2015-2020

Published Date: 23 October 2014

Motivation for treatment in patients with substance use disorder: personal volunteering versus legal/familial enforcement

Bilici R, Yazici E, Tufan AE, Mutlu E, Ä°zci F, Ugurlu GK

Neuropsychiatric Disease and Treatment 2014, 10:1599-1604

Published Date: 30 August 2014

Dissociative symptoms reflect levels of tumor necrosis factor alpha in patients with unipolar depression

Bizik G, Bob P, Raboch J, Pavlat J, Uhrova J, Benakova H, Zima T

Neuropsychiatric Disease and Treatment 2014, 10:675-679

Published Date: 25 April 2014

Building a new Rasch-based self-report inventory of depression

Balsamo M, Giampaglia G, Saggino A

Neuropsychiatric Disease and Treatment 2014, 10:153-165

Published Date: 28 January 2014

Measuring quality of sleep and autonomic nervous function in healthy Japanese women

Sato M, Yasuhara Y, Tanioka T, Iwasa Y, Miyake M, Yasui T, Tomotake M, Kobayashi H, Locsin RC

Neuropsychiatric Disease and Treatment 2014, 10:89-96

Published Date: 17 January 2014